CBT or AIQUY: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2200099/cbt-or-aiquy-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2200099
Dec 19, 2023 - CBT vs. AIQUY: Which Stock Is the Better Value Option?
0
Why Cabot (CBT) is a Great Dividend Stock Right Now
https://www.zacks.com/stock/news/2207088/why-cabot-cbt-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2207088
Jan 08, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cabot (CBT) have what it takes? Let's find out.
0
CBT or AIQUY: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2207097/cbt-or-aiquy-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2207097
Jan 08, 2024 - CBT vs. AIQUY: Which Stock Is the Better Value Option?
0
Best Value Stocks to Buy for January 15th
https://www.zacks.com/commentary/2210014/best-value-stocks-to-buy-for-january-15th?cid=CS-ZC-FT-zacks_1_rank_additions|value_additions-2210014
Jan 15, 2024 - RGA, PAX and CBT made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 15, 2024.
0
Arkema (ARKAY) Backs Tiamat for Lithium-Free Battery Innovation
https://www.zacks.com/stock/news/2209961/arkema-arkay-backs-tiamat-for-lithium-free-battery-innovation?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2209961
Jan 15, 2024 - Arkema (ARKAY) invests in Tiamat, accelerating the development of lithium-free solutions and supporting the construction of a dedicated 5 GWh Giga-factory in France.
0
Are You Looking for a High-Growth Dividend Stock?
https://www.zacks.com/stock/news/2215152/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2215152
Jan 24, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cabot (CBT) have what it takes? Let's find out.
0
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
https://www.zacks.com/stock/news/2230299/better-therapeutics-bttx-cbt-gains-fda-s-breakthrough-status?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2230299
Feb 22, 2024 - Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
0
Why Cabot (CBT) is a Top Value Stock for the Long-Term
https://www.zacks.com/stock/news/2195457/why-cabot-cbt-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2195457
Dec 08, 2023 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
Cabot (CBT) Upgraded to Buy: What Does It Mean for the Stock?
https://www.zacks.com/stock/news/2207125/cabot-cbt-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2207125
Jan 08, 2024 - Cabot (CBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
ArcelorMittal (MT) Rejects Italy Government's Stake Plan in ADI
https://www.zacks.com/stock/news/2207547/arcelormittal-mt-rejects-italy-government-s-stake-plan-in-adi?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2207547
Jan 09, 2024 - ArcelorMittal (MT) rejects the Italian government's proposal to acquire a controlling stake in ADI, a major steel plant, citing reluctance to commit financially, sparking concerns over the future of the financially troubled ex-Ilva plant in Taranto.
0
Pages: 12
Page 1